The Apex Times
Above the Noise
Business Wire
BusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex Times
Back to front
Charles River steps into Eli Lilly’s TuneLab workflow, offering standardized nonclinical testing for AI-designed drugs
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 26, 10:46 AM EDT

Charles River steps into Eli Lilly’s TuneLab workflow, offering standardized nonclinical testing for AI-designed drugs

A new collaboration links Charles River Laboratories’ standardized nonclinical testing services with Eli Lilly’s Lilly TuneLab, a platform aimed at helping developers evaluate candidate medicines created with AI and machine learning.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Eli Lilly is deepening its push into AI-assisted drug development with a collaboration that brings Charles River Laboratories into the early testing pipeline. The June 2026 announcement described a relationship in which Charles River will provide standardized nonclinical testing services for AI and machine-learning-enabled biotech companies using Lilly’s TuneLab drug discovery program.

Nonclinical testing refers to pre-human studies conducted to generate safety and biological information before a medicine is tested in people. In the collaboration, Charles River’s role is to supply those services in a standardized way, an approach intended to reduce variability across experiments and help AI-focused sponsors move faster from computational design to laboratory evidence.

The company framed the effort around TuneLab, which is positioned as part of Lilly’s broader strategy to apply AI and automation to drug discovery decisions. TuneLab is described in the report as the mechanism through which AI/ML-enabled companies can access Lilly’s framework for evaluating drug candidates, and through which Charles River’s testing capabilities are integrated.

For Charles River, the arrangement highlights a shift in how contract research organizations may compete and win work in an AI-era pipeline. If more biotech programs originate from model-generated hypotheses, sponsors may seek testing partners that can run consistent studies across multiple candidate series, rather than building bespoke procedures from scratch each time.

Lilly’s cooperation with an external testing provider also points to a practical constraint in AI drug development: even the best models still need laboratory validation. Standardized testing services can matter because results from nonclinical work often influence which candidates get advanced, how protocols are iterated, and whether teams have sufficient evidence to proceed to more expensive development stages.

Industry watchers typically view early-stage nonclinical execution as a combination of scientific rigor and operational reliability. Standardization can help when multiple AI-generated candidates need to be compared using similar methods and endpoints, lowering the risk that differences in process rather than candidate biology explain outcome gaps.

The collaboration details disclosed in the reporting are comparatively high level. The announcement, as characterized in the post, does not specify study types beyond nonclinical testing, timeline targets, financial terms, or the breadth of testing platforms Charles River will support within TuneLab. It also does not clarify whether Charles River is the exclusive testing provider for TuneLab users or whether the arrangement covers all TuneLab programs or only certain therapeutic areas.

What to watch next is how the companies operationalize the partnership, particularly whether they publish additional information on the standardized testing scope, integration steps for AI/ML sponsors, and any measurable improvements in turnaround time or decision-making metrics. Updates on adoption by biotech partners using TuneLab would also be a key announcement of whether Lilly and Charles River’s model for standardized nonclinical testing gains traction.

Why It Matters

  • The deal underscores how AI drug discovery still depends on conventional laboratory validation, with standardized testing aimed at making candidate comparisons more consistent.
  • For contract research organizations, partnerships like this suggest competitive differentiation may increasingly come from repeatable execution across fast-moving AI pipelines.
  • If TuneLab adoption expands, Charles River could see more demand tied to early translational studies rather than later-stage work alone.
  • The absence of detail on exclusivity and scope leaves uncertainty about how much of TuneLab’s work Charles River will handle.

Sources

Key Facts

  • Eli Lilly announced a collaboration in June 2026 that connects Charles River Laboratories to Lilly’s TuneLab program.
  • Under the collaboration, Charles River will provide standardized nonclinical testing services for AI/ML-enabled biotech companies using TuneLab.
  • Nonclinical testing is pre-human laboratory work used to generate safety and biological evidence for candidate medicines.
  • The reporting describes the effort as a way to support the evaluation of AI-designed drug candidates through a more standardized testing approach.
  • The post does not disclose financial terms, the exact testing study types beyond nonclinical testing, or performance targets.

Healthcare Related

Charles River steps into Eli Lilly’s TuneLab workflow, offering standardized nonclinical testing for AI-designed drugs | The Apex Times